CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
NCT04205643
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
548
Enrollment
INDUSTRY
Sponsor class
Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL:
CT-P13 SC (Infliximab)
OTHER:
Placebo SC
Sponsor
Celltrion